Eric Easom - 29 Mar 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Chief Executive Officer, Director
Signature: /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Issuer symbol: ANTX
Transactions as of: 29 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 31 Mar 2022, 20:15:20 UTC
Previous filing: 24 Mar 2022
Next filing: 16 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Conversion of derivative security		+4,907			4,907	29 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANTX	Series A Convertible Preferred Stock	Conversion of derivative security	$0	-4,907	-100%	$0.000000^*	0	29 Mar 2022	Common Stock	4,907		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.